Literature DB >> 22072598

Investigation of different cell types and gel carriers for cell-based intervertebral disc therapy, in vitro and in vivo studies.

H B Henriksson1,2, M Hagman1, M Horn3, A Lindahl1, H Brisby2.   

Abstract

Biological treatment options for the repair of intervertebral disc damage have been suggested for patients with chronic low back pain. The aim of this study was to investigate possible cell types and gel carriers for use in the regenerative treatment of degenerative intervertebral discs (IVD). In vitro: human mesenchymal cells (hMSCs), IVD cells (hDCs), and chondrocytes (hCs) were cultivated in three gel types: hyaluronan gel (Durolane®), hydrogel (Puramatrix®), and tissue-glue gel (TISSEEL®) in chondrogenic differentiation media for 9 days. Cell proliferation and proteoglycan accumulation were evaluated with microscopy and histology. In vivo: hMSCs or hCs and hyaluronan gel were co-injected into injured IVDs of six minipigs. Animals were sacrificed at 3 or 6 months. Transplanted cells were traced with anti-human antibodies. IVD appearance was visualized by MRI, immunohistochemistry, and histology. Hyaluronan gel induced the highest cell proliferation in vitro for all cell types. Xenotransplanted hMSCs and hCs survived in porcine IVDs for 6 months and produced collagen II in all six animals. Six months after transplantation of cell/gel, pronounced endplate changes indicating severe IVD degeneration were observed at MRI in 1/3 hC/gel, 1/3 hMSCs/gel and 1/3 gel only injected IVDs at MRI and 1/3 hMSC/gel, 3/3 hC/gel, 2/3 gel and 1/3 injured IVDs showed positive staining for bone mineralization. In 1 of 3 discs receiving hC/gel, in 1 of 3 receiving hMSCs/gel, and in 1 of 3 discs receiving gel alone. Injected IVDs on MRI results in 1 of 3 hMSC/gel, in 3 of 3 hC/gel, in 2 of 3 gel, and in 1 of 3 injured IVDs animals showed positive staining for bone mineralization. The investigated hyaluronan gel carrier is not suitable for use in cell therapy of injured/degenerated IVDs. The high cell proliferation observed in vitro in the hyaluronan could have been a negative factor in vivo, since most cell/gel transplanted IVDs showed degenerative changes at MRI and positive bone mineralization staining. However, this xenotransplantation model is valuable for evaluating possible cell therapy strategies for human degenerated IVDs.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Keywords:  chondrocytes; extracellular matrix; gel carrier; human mesenchymal stem cells; hyaluronan; intervertebral disc; xenotransplantation

Mesh:

Substances:

Year:  2011        PMID: 22072598     DOI: 10.1002/term.480

Source DB:  PubMed          Journal:  J Tissue Eng Regen Med        ISSN: 1932-6254            Impact factor:   3.963


  17 in total

Review 1.  Stem cell therapy for intervertebral disc regeneration: obstacles and solutions.

Authors:  Daisuke Sakai; Gunnar B J Andersson
Journal:  Nat Rev Rheumatol       Date:  2015-02-24       Impact factor: 20.543

Review 2.  Disc cell therapies: critical issues.

Authors:  Marta Tibiletti; Nevenka Kregar Velikonja; Jill P G Urban; Jeremy C T Fairbank
Journal:  Eur Spine J       Date:  2014-02-08       Impact factor: 3.134

Review 3.  Cell therapy for the degenerating intervertebral disc.

Authors:  Wei Tong; Zhouyu Lu; Ling Qin; Robert L Mauck; Harvey E Smith; Lachlan J Smith; Neil R Malhotra; Martin F Heyworth; Franklin Caldera; Motomi Enomoto-Iwamoto; Yejia Zhang
Journal:  Transl Res       Date:  2016-11-28       Impact factor: 7.012

Review 4.  Stem Cell Therapies for Treatment of Discogenic Low Back Pain: a Comprehensive Review.

Authors:  Ivan Urits; Alexander Capuco; Medha Sharma; Alan D Kaye; Omar Viswanath; Elyse M Cornett; Vwaire Orhurhu
Journal:  Curr Pain Headache Rep       Date:  2019-07-29

5.  Stemming the Degeneration: IVD Stem Cells and Stem Cell Regenerative Therapy for Degenerative Disc Disease.

Authors:  V Sivakamasundari; Thomas Lufkin
Journal:  Adv Stem Cells       Date:  2013

6.  Vaccine self-assembling immune matrix is a new delivery platform that enhances immune responses to recombinant HBsAg in mice.

Authors:  Rafaella F Q Grenfell; Lisa M Shollenberger; E Farah Samli; Donald A Harn
Journal:  Clin Vaccine Immunol       Date:  2015-01-21

7.  Disc cell therapy with bone-marrow-derived autologous mesenchymal stromal cells in a large porcine disc degeneration model.

Authors:  G W Omlor; S Lorenz; A G Nerlich; T Guehring; W Richter
Journal:  Eur Spine J       Date:  2018-08-23       Impact factor: 3.134

Review 8.  Cell sources for nucleus pulposus regeneration.

Authors:  Nevenka Kregar Velikonja; Jill Urban; Mirjam Fröhlich; Cornelia Neidlinger-Wilke; Dimitris Kletsas; Urska Potocar; Sarah Turner; Sally Roberts
Journal:  Eur Spine J       Date:  2013-12-03       Impact factor: 3.134

Review 9.  [Research progress of hydrogel used for regeneration of nucleus pulposus in intervertebral disc degeneration].

Authors:  Kun Shi; Yong Huang; Leizhen Huang; Jingcheng Wang; Yuhan Wang; Ganjun Feng; Limin Liu; Yueming Song
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2020-03-15

Review 10.  Animal models of regenerative medicine for biological treatment approaches of degenerative disc diseases.

Authors:  Demissew Shenegelegn Mern; Tanja Walsen; Anja Beierfuß; Claudius Thomé
Journal:  Exp Biol Med (Maywood)       Date:  2020-11-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.